Biogen Idec reports 6 more PML cases; Amgen CEO 'aggressively' seeking international buys;

@FiercePharma: Does your severance pay beat Eli Lilly's? Report | Follow @FiercePharma

> Six more patients taking Biogen Idec's (BIIB.O) multiple sclerosis drug Tysabri have developed a potentially deadly brain infection known as PML, the company said. Report

> Amgen (AMGN.O) is "aggressively" looking at acquisitions, particularly opportunities for international expansion, Chief Executive Kevin Sharer said. Report

> FDA warned several drugmakers--including Eisai, Cumberland Pharmaceuticals and Sepracor--about promotions and advertising it considers misleading. Report

> Expanding off-label use of Genentech's Avastin rather than the company's more expensive Lucentis to treat a certain type of macular degeneration could save Medicare $500 million per year, according to an unpublished study reviewed by the Wall Street JournalReport

> Bayer (BAYGn.DE) said Teva's (TEVA.TA) U.S. unit admitted in a court proceeding on Wednesday that some of the information included on packages of its oral contraceptive Gianvi--a copycat form of Bayer's Yaz--was false and agreed to correct its labeling. Report

> Five months after Johnson & Johnson drugmaking divison McNeil Consumer Healthcare recalled millions of Tylenol and Motrin products, store shelves across the nation are still bare of these medications. Report

> The FDA is warning consumers about a product sold as "generic Tamiflu" on the Internet; it's not the antiviral drug at all but an antibiotic ingredient similar to penicillin. Release

Biotech News

 @FierceBiotech: EXCLUSIVE: Pfizer plans to move fast on rare disease pacts. Story | Follow @FierceBiotech

 @JohnCFierce: GW is developing Sativex (with Otsuka) for cancer pain in the US; significantly more lucrative than the MS approvals it's getting in Europe. | Follow @JohnCFierce

> PacBio gets $50M investment from Gen-Probe. Story

> GW Pharma's cannabis drug Sativex wins landmark approval. Article

> Phase III osteoarthritis pain trial is a winner for Pfizer. News

> FerroKin rounds up $12M for iron overload treatment. Report

> Adolor shares sink after placebo effect scuttles PhIIa pain trial. Story

And Finally... Emergency room visits tied to the abuse of prescription painkillers have jumped 111 percent over five years, an alarming increase that threatens the American public health system, officials said. Report